GlassScriptPhysician profile
Michael W Lankiewicz
NPI 1982717930
$2,284.92
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,540 · 2020: $478 · 2023: $230 · 2024: $36.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $379.60 | 2019-2023 | |
| Janssen Biotech, INC. | $246.51 | 2019-2020 | |
| Seagen INC. | $107.67 | 2019 | |
| Amgen INC. | $105.44 | 2019 | |
| Abbvie INC. | $98.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $89.63 | 2019-2020 | |
| Verastem, INC. | $82.07 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $79.53 | 2019-2020 | |
| Celgene Corporation | $74.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $68.77 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $68.01 | 2019-2020 | |
| Kite Pharma, INC. | $63.66 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $62.30 | 2019 | |
| Merck Sharp & Dohme LLC | $61.25 | 2019-2020 | |
| Pfizer INC. | $61.06 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $60.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $59.32 | 2019-2020 | |
| Gilead Sciences, INC. | $50.06 | 2019 | |
| Rigel Pharmaceuticals, INC. | $44.73 | 2019-2020 | |
| Partner Therapeutics, INC. | $38.08 | 2019 | |
| Haemonetics Corporation | $36.88 | 2024 | Teg6s Hemostasis System |
| Astellas Pharma US INC | $36.54 | 2020 | |
| Daiichi Sankyo INC. | $32.06 | 2019 | |
| Agios Pharmaceuticals, INC. | $29.29 | 2019-2020 | |
| Eusa Pharma (US) LLC | $28.97 | 2019 | |
| Amag Pharmaceuticals, INC. | $28.59 | 2019-2020 | |
| Incyte Corporation | $22.58 | 2019 | |
| Genentech USA, INC. | $22.13 | 2020 | |
| Spectrum Pharmaceuticals INC. | $21.30 | 2019 | |
| Shire North American Group INC | $18.41 | 2019 | |
| Stemline Therapeutics INC. | $15.90 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.76 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lankiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.